DRMA’s 2023 Market Dance: Down -87.25% – Time to Invest?

The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. The metric has seen a significant loss of -87.25% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -63.08%. Over the past 30 days, the price of DRMA has fallen by 30.38%. And in the last five days, it has surged by 24.54%.

The stock of Dermata Therapeutics Inc (DRMA) is currently priced at $0.83. In the last session, the stock climbed significantly, topping out at $0.8344 after opening at $0.6699. The day’s lowest price was $0.6452 before the stock closed at $0.70.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Dermata Therapeutics Inc’s market performance has been unstable in recent times. The company’s stock hit a 1-year high of $11.84 on 11/21/22 and a low of $0.56 for the same time frame on 11/13/23.

52-week price history of DRMA Stock

Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Dermata Therapeutics Inc’s current trading price is -92.95% away from its 52-week high, while its distance from the 52-week low is 48.63%. The stock’s price range during this period has varied between$0.56 and $11.84. The Dermata Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 0.6 million for the day, a figure considerably higher than their average daily volume of 0.27 million over last three months.

Market Capitalization vs. Financial Performance: A Comparative Study

Dermata Therapeutics Inc (DRMA) has experienced a quarterly decline of -26.81% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.66M and boasts a workforce of 8 employees.

Combining Moving Average and Trading Volume Data for Better Market Insight

Based on Barchart.com data, the company’s moving average over the 100-day period was 1.0927, with a change in price of -0.8856. Similarly, Dermata Therapeutics Inc recorded 209,480 in trading volume during the last 100 days, posting a change of -51.49%.

DRMA’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look

The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for DRMA stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.

DRMA Stock Stochastic Average

Dermata Therapeutics Inc’s raw stochastic average for the past 50 days is presently 44.86%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 66.01%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 44.00% and 32.99%, respectively.

Leave a Reply

Your email address will not be published. Required fields are marked *

On Key

Related Posts